Genentech's Lunsumio VELO Gains FDA Approval As Subcutaneous Treatment Option For Relapsed Or Refractory Follicular Lymphoma

Benzinga · 3d ago
  • Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute 
  • Availability of Lunsumio VELO allows treatment aligned to people's clinical needs and personal preferences 
  • Approval supported by data demonstrating compelling complete response rate in third-line or later follicular lymphoma, which typically becomes harder to treat after each relapse